检索结果-南通市图书馆

The state-of-the-arts of the study on grid interconnection between Iberian Peninsula and West Maghreb region

Global Energy Interconnection 2018年第1期1卷 20-28页

作者： Hong Shen Qian Dai Qi Wu Junling Wu Qinyong Zhou Jiarong Wang Wei Yang Rui Pestana ricardo pastor Global Energy Interconnection Development and Cooperation Organization No.8 Xuanwumennei StreetXicheng DistrictBeijing 100031P.R.China China Electric Power Research Institute Haidian DistrictBeijing 100192China North China Electric Power University Changping DistrictBeijingChina102206 R&D Nester–Centro de Investigacao em Energia REN-State Grid RuaCidade de GoaB 2685-038 SacavémLisbonPortugal.

With the change of energy structure in Europe and the trend of diversification of energy supply, the interconnection of the power grid in the Mediterranean region has gradually become a hotspot in European energy research. This paper introduces the power supply, load demand, power grid construction and the present situation of multinational interregional interconnection in the Iberian Peninsula of the Tour of Mediterranean in Europe(Portugal and Spain) and the Western Maghreb countries(Morocco and Algeria). And the driving force and influence factors of regional power grid interconnection are also analyzed. According to the MEDGRID project aimed at realizing the Mediterranean power grid interconnection, this paper presents the interconnection schemes of the Iberian Peninsula and the Western Maghreb. Furthermore, the subsequent technical problems need to be solved are also expounded.

关键词： Mediterranean power grid Interconnection driving factor POR-MAR interconnected power network

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Dendritic cell vaccination in glioblastoma after fluorescenceguided resection

引用

World Journal of Clinical Oncology 2012年第11期3卷 142-149页

作者： ricardo Diez Valle Ascension Lopez-Diaz de Cerio Susana Inoges Sonia Tejada Fernando pastor Helena Villanueva Jaime Gallego Jaime Espinos Javier Aristu Miguel Angel Idoate Enrique Andreu Maurizio Bendandi Department of Neurosurgery University of Navarra Hospital 31008 Pamplona Navarra Spain Lab of Immunotherapy CIMA 31008 Pamplona Navarra Spain Immunotherapy Program University of Navarra Hospital 31008 Pamplona Navarra Spain Department of Neurology University of Navarra Hospital 31008 Pamplona Navarra Spain Department of Oncology University of Navarra Hospital 31008 Pamplona Navarra Spain Department of Pathology University of Navarra Hospital 31008 Pamplona Navarra Spain Cell Therapy Area University of Navarra Hospital 31008 Pamplona Navarra Spain

AIM: To assess whether the addition of a customized, active immunotherapy to standard of care including fluorescence-guided surgery, may provide hints of an improved survival for patients with poor-prognosis, incurable glioblastoma multiform. METHODS: Preliminary to our ongoing, phase-Ⅱ clinical trial, we conducted a small pilot study enrolling five consecutive patients with resectable glioblastoma. In terms of Recursive Partitioning Analysis, four patientswere class Ⅴ and one was class Ⅳ. In all five cases, fluorescence-guided surgery was employed, followed by rapid steroid discontinuation. Patients were then treated with a combination of standard radio-chemotherapy with temozolomide and tumor lysate-pulsed, mature dendritic cell-based ***: Though all five patients ultimately progressed, with any further treatment left to the sole decision of the treating oncologist, active immunotherapy was very well tolerated and induced specific immune responses in all three patients for whom enough material was available for such an assessment. Median progression-free survival was 16.1 mo. Even more important, median and mean overall survival were 27 mo and 26 mo, respectively. Three patients have died with an overall survival of 9 mo, 27 mo and 27.4 mo, while the other two are still alive at 32 mo and 36 mo, the former receiving treatment with bevacizumab, while the latter has now been off therapy for 12 mo. Four of five patients were alive at two ***: Active immunotherapy with tumor lysate-pulsed, autologous dendritic cells is feasible, safe, well tolerated and biologically efficacious. A phase-Ⅱ study is ongoing to possibly improve further on our very encouraging clinical results.

关键词： Immunotherapy Glioblastoma Fluorescence-guided surgery Dendritic cells Tumor-lysate

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：